These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 2249013)

  • 1. High BCM serum levels in patients with non breast tumors: first results.
    Allende T; Vizoso F; Roiz C; Fueyo A; Lennartz L; Ruibal A
    Bull Cancer; 1990; 77(10):1031-2. PubMed ID: 2249013
    [No Abstract]   [Full Text] [Related]  

  • 2. BCM-IMx and CA15.3 serum levels in patients with breast cancer: a comparative study.
    Allende MT; Fernández Llana B; Rodriguez Alvarez JM; Roiz MC; Vizoso F; Ruibal A
    Bull Cancer; 1991; 78(8):743-5. PubMed ID: 1932840
    [No Abstract]   [Full Text] [Related]  

  • 3. [Serum BCM in patients with nontumorous diseases. Preliminary results].
    Allende MT; Vizoso F; Sampedro A; Ruibal A
    Rev Clin Esp; 1990 Oct; 187(5):254-5. PubMed ID: 2102542
    [No Abstract]   [Full Text] [Related]  

  • 4. BCM-IMx behaviour in patients with lung diseases.
    Allende MT; Hernández J; Fernández Fernández M; Fernández Llana B; Suarez B; Ruibal A
    Bull Cancer; 1991; 78(9):843-5. PubMed ID: 1661198
    [No Abstract]   [Full Text] [Related]  

  • 5. MCA performance in preoperative breast cancer patients.
    Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
    Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preliminary experience with BCM-IMx as a pretreatment marker of breast tumors].
    Fernández Llana B; Fernández Fernández M; Suárez B; Allende MT
    Rev Clin Esp; 1992 Mar; 190(4):209. PubMed ID: 1589619
    [No Abstract]   [Full Text] [Related]  

  • 7. [Increase in serum mucin-like carcinoma-associated antigen (MCA) in patients with chronic liver diseases].
    Soriano A; Pombo L; Sagredo E; Ruibal A
    Med Clin (Barc); 1988 Nov; 91(17):675. PubMed ID: 3230974
    [No Abstract]   [Full Text] [Related]  

  • 8. [Tumor markers in the diagnosis and prognosis of breast cancer].
    Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
    Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
    Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
    Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A comparative evaluation of tumor markers (TPA and CEA) in various malignant neoplasms at an advanced stage].
    Meregalli M; Antoniazzi V; Torchio G; Colombo E; Bocchi M; Sonzini E; Lino S
    Minerva Med; 1989 Apr; 80(4):345-7. PubMed ID: 2725935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors.
    Hernández L; Nuñez-Villarl MJ; Martínez-Arribas F; Pollán M; Schneider J
    Anticancer Res; 2005; 25(1B):451-4. PubMed ID: 15816610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The correlation between the serum concentrations of BCM (breast cancer mucin), CA549 and estradiol in women with breast macrocysts].
    Vizoso F; Allende MT; Fueyo A; Ruibal A
    Med Clin (Barc); 1991 Feb; 96(5):198. PubMed ID: 2033998
    [No Abstract]   [Full Text] [Related]  

  • 13. [CA125 in patients with pleural effusion--in comparison with ascites patients].
    Kawabe T; Hirano M; Mohri M; Sugimoto T; Nagata Y; Hisada M; Muto H; Unuma T; Momose T; Naka H
    Rinsho Byori; 1987 Aug; 35(8):905-9. PubMed ID: 3480365
    [No Abstract]   [Full Text] [Related]  

  • 14. [Levels of circulating tumor-associated glycoprotein (TAG-72) in patients with carcinoma using a novel tumor marker, CA 72-4].
    Ohuchi N; Matoba N; Taira Y; Takahashi K; Sakai N; Sato K; Fujita N; Mochizuki F; Nishihira T; Mori S
    Gan To Kagaku Ryoho; 1988 Sep; 15(9):2767-72. PubMed ID: 3166366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mucin markers in metastatic breast cancer].
    Bieglmayer C; Breitenecker G; Szepesi T
    Gynakol Rundsch; 1990; 30 Suppl 1():142-4. PubMed ID: 2079249
    [No Abstract]   [Full Text] [Related]  

  • 16. [The cytosolic concentrations of CAM26 and CAM29 in breast tumors classified according to the clinical stage].
    Fernández M; Suárez B; González C; Allende MT
    Rev Clin Esp; 1992 May; 190(9):480-1. PubMed ID: 1626101
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of human monoclonal antibody to detect serum antigen in patients with breast cancer.
    Strelkauskas AJ; Aldenderfer PH; Warner GA
    Anticancer Res; 1989; 9(6):1863-8. PubMed ID: 2627133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
    Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
    Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of tumour-associated antigens in breast cancer primary tissue compared with serum levels.
    Cannon PM; Ellis IO; Blamey RW; Bell J; Elston CW; Robertson JF
    Eur J Surg Oncol; 1993 Dec; 19(6):523-7. PubMed ID: 8270037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a new tumor associated antigen from mammary carcinoma cells by monoclonal antibodies.
    Czuppon AB
    Biochem Int; 1987 Aug; 15(2):359-72. PubMed ID: 3435529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.